The impact of approved anti-obesity medications on osteoarthritis.

IF 2.5 3区医学 Q3 PHARMACOLOGY & PHARMACY

Expert Opinion on Pharmacotherapy Pub Date : 2024-08-01 Epub Date: 2024-08-12 DOI:10.1080/14656566.2024.2391524

Onur Baser, Katarzyna Rodchenko, Elizabeth Vivier, Isabel Baser, Yuanqing Lu, Munira Mohamed

{"title":"The impact of approved anti-obesity medications on osteoarthritis.","authors":"Onur Baser, Katarzyna Rodchenko, Elizabeth Vivier, Isabel Baser, Yuanqing Lu, Munira Mohamed","doi":"10.1080/14656566.2024.2391524","DOIUrl":null,"url":null,"abstract":"Background: Obesity has been established as a significant risk factor for osteoarthritis. Anti-obesity medications (AOMs) have demonstrated efficacy in weight management. However, potential impact on osteoarthritis risk remains uncertain.Methods: This retrospective cohort study used Kythera data from NOV2022 to JULY2024. Patients with obesity using AOMs were identified through diagnosis and prescription claims for tirzepatide, semaglutide, or liraglutide between 1NOV2023 and 31JAN2024, with a 6-month follow-up to assess OA risk. OA risk, analyzed using Cox regression and propensity score matching, controlled for comorbidities and sociodemographic factors.Results: There were 39,394 patients living with obesity using AOM (23,933 semaglutide 12,854 tirzepatide, 2,607 liraglutide) and 72,405 without AOM use. The adjusted osteoarthritis risk was 27% % lower in AOM users than in non-users (hazard ratio (HR) = 073, 95% CI (0.67-0.79), p < 0.01). Among AOMs, tirzepatide was associated with a significantly lower osteoarthritis (OA) risk compared to semaglutide (HR = 0.57, 95% CI: 0.50-0.65, p < 0.0001). Liraglutide was linked to a significantly higher OA risk vs tirzepatide (HR = 1.63, 95% CI: 1.23-2.15, p = 0.0007).Conclusions: AOM use was associated with a significantly lower risk of OA and may be an effective obesity management intervention.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14656566.2024.2391524","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Obesity has been established as a significant risk factor for osteoarthritis. Anti-obesity medications (AOMs) have demonstrated efficacy in weight management. However, potential impact on osteoarthritis risk remains uncertain.

Methods: This retrospective cohort study used Kythera data from NOV2022 to JULY2024. Patients with obesity using AOMs were identified through diagnosis and prescription claims for tirzepatide, semaglutide, or liraglutide between 1NOV2023 and 31JAN2024, with a 6-month follow-up to assess OA risk. OA risk, analyzed using Cox regression and propensity score matching, controlled for comorbidities and sociodemographic factors.

Results: There were 39,394 patients living with obesity using AOM (23,933 semaglutide 12,854 tirzepatide, 2,607 liraglutide) and 72,405 without AOM use. The adjusted osteoarthritis risk was 27% % lower in AOM users than in non-users (hazard ratio (HR) = 073, 95% CI (0.67-0.79), p < 0.01). Among AOMs, tirzepatide was associated with a significantly lower osteoarthritis (OA) risk compared to semaglutide (HR = 0.57, 95% CI: 0.50-0.65, p < 0.0001). Liraglutide was linked to a significantly higher OA risk vs tirzepatide (HR = 1.63, 95% CI: 1.23-2.15, p = 0.0007).

Conclusions: AOM use was associated with a significantly lower risk of OA and may be an effective obesity management intervention.

查看原文本刊更多论文

已获批准的抗肥胖药物对骨关节炎的影响。

背景：肥胖已被确定为骨关节炎的一个重要风险因素。抗肥胖药物（AOMs）已被证明具有控制体重的功效。然而，对骨关节炎风险的潜在影响仍不确定：这项回顾性队列研究使用了 Kythera 从 2022 年 11 月至 2024 年 7 月的数据。在 2023 年 11 月 1 日至 2024 年 1 月 31 日期间，使用 AOMs 的肥胖症患者通过诊断和处方报销确定为替齐帕肽、赛马鲁肽或利拉鲁肽患者，随访 6 个月以评估 OA 风险。采用Cox回归和倾向得分匹配法分析OA风险，并控制合并症和社会人口学因素：39,394名肥胖症患者使用了AOM（23,933例塞马鲁肽、12,854例替扎帕肽、2,607例利拉鲁肽），72,405名患者未使用AOM。AOM使用者的调整后骨关节炎风险比未使用者低27%（危险比（HR）= 073，95% CI (0.67-0.79)，p p = 0.0007）：使用AOM可显著降低罹患OA的风险，可能是一种有效的肥胖管理干预措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Pharmacotherapy 医学-药学

CiteScore

5.60

自引率

3.10%

发文量

163

审稿时长

4-8 weeks

期刊介绍： Expert Opinion on Pharmacotherapy is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds mainly of chemical/synthetic origin, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.